Laboratory Tests for Inflammatory Bowel Disease

Core Laboratory Panel for IBD Assessment

The European Crohn’s and Colitis Organisation recommends obtaining a complete blood count, C-reactive protein, erythrocyte sedimentation rate, serum electrolytes, liver enzymes, serum albumin, renal function, and fecal calprotectin for patients with suspected or known IBD, while excluding infectious causes through stool cultures and Clostridium difficile toxin testing 1, 2, 3
A complete blood count (CBC) including hemoglobin, leukocyte count, and platelet count is essential to detect anemia, leukocytosis, and thrombocytosis that commonly accompany active disease 1, 2, 4
C-reactive protein (CRP) is superior to erythrocyte sedimentation rate (ESR) for evaluating acute disease activity, particularly in Crohn's disease where it correlates better with endoscopic findings 1, 5
Serum electrolytes are necessary to identify imbalances from diarrhea and malabsorption 1, 2
Liver enzymes should be assessed to evaluate hepatobiliary involvement and monitor for medication-related toxicity 1, 3
Serum albumin and pre-albumin are used to evaluate nutritional status and degree of inflammation 2, 3
Renal function (creatinine and urea) should be assessed to evaluate kidney status and guide medication dosing 1, 6

Fecal calprotectin is the most sensitive non-invasive marker for intestinal inflammation, useful for diagnosis, assessing disease severity, and monitoring treatment response 1, 4, 7
Stool cultures are necessary to exclude bacterial pathogens 1, 2
Clostridium difficile toxin testing is mandatory in all suspected flares, as C. difficile infection is associated with higher mortality and increased healthcare utilization 1, 2, 4

The American Gastroenterological Association recommends hemoglobin thresholds of <13 g/dL for men, <12 g/dL for women, <11 g/dL for pregnant women and children 6 months to 5 years 8, 6
Red blood cell indices, including Mean corpuscular volume (MCV) and red cell distribution width (RDW), are used to differentiate anemia types 8, 6
Reticulocyte count is necessary to assess bone marrow response 8
Serum ferritin <30 μg/L indicates iron deficiency in patients without active inflammation 8, 6
Serum ferritin up to 100 μg/L may still represent iron deficiency when inflammation is present 8, 6
Transferrin saturation <20% with ferritin >100 μg/L suggests anemia of chronic disease 6

Diagnosis requires a combination of clinical history, laboratory findings, endoscopic evaluation with biopsies, and exclusion of infectious causes—no single gold standard test exists 9, 4, 7
Laboratory abnormalities in active IBD typically include anemia, leukocytosis, thrombocytosis, elevated liver enzymes, hypoalbuminemia, and increased inflammatory markers 1, 5
Iron studies, including serum iron, total iron-binding capacity, and transferrin saturation, should be obtained at initial diagnosis 4
Vitamin D level should be assessed at diagnosis 4
Immunization status should be documented 4

Stable outpatients should have complete blood count and CRP monitored regularly, though specific intervals depend on disease activity and treatment 8
Patients with extensive small bowel resection or ileal disease should have vitamin B12 and folate assessed more frequently than annually 8
During flares, repeat infectious workup including C. difficile and consider cytomegalovirus testing 4

Normal CRP does not exclude active IBD, as some patients (particularly with ulcerative colitis) may have active disease without CRP elevation 1, 5
CRP correlates better with endoscopic activity in Crohn's disease than ulcerative colitis 1, 10
Fecal calprotectin lacks specificity to distinguish IBD from other causes of inflammation including infections and medication effects 4, 7
Home-based calprotectin testing provides reliable monitoring and enables eHealth approaches 4

The American Gastroenterological Association recommends C-reactive protein (CRP) as the primary serum marker for Crohn's disease management, with a clinically relevant cutoff of 5 mg/L used to assess inflammatory activity 11, 12, 13
CRP is the most widely used and validated serum biomarker for Crohn's disease, with a standard cutoff of 5 mg/L used in clinical practice to detect endoscopic inflammation 11, 13

CRP correlates significantly better with endoscopic disease activity in Crohn's disease compared to ulcerative colitis, making it particularly valuable for this condition 14

Normal CRP (<5 mg/L) combined with fecal calprotectin <150 mg/g effectively rules out active inflammation, avoiding unnecessary endoscopy with 81% sensitivity and 72% specificity 15, 16
Elevated CRP in asymptomatic patients requires endoscopic confirmation before treatment escalation, as biomarkers alone should not drive therapeutic decisions in this setting 15
CRP >5 mg/L in patients with moderate to severe symptoms strongly suggests endoscopic activity and may preclude the need for routine endoscopic assessment before treatment adjustment 15
CRP is less reliable than fecal calprotectin for detecting postoperative recurrence in low-risk patients on pharmacologic prophylaxis 15, 16

Elevated baseline CRP predicts better response to anti-TNF therapy and other biologic agents, as these medications work particularly well in patients with high inflammatory burden 14
CRP >45 mg/L in hospitalized patients with severe colitis predicts need for colectomy when measured 48-72 hours after admission alongside stool frequency 14